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I must start by thanking Jane Gitschier for that very
kind and thorough introduction. Would you believe I
have tears in my eyes? At the onset, I must say that I
am extremely honored to have received the 2004 Wil-
liam Allan Award from the American Society of Human
Genetics. This honor was beyond my wildest dreams
when I started my career in human genetics.
In my lecture, I will try to outline which parts of my
career I feel contributed to my receiving this award. I’m
here today to review a little bit about the cloning of the
gene responsible for Duchenne muscular dystrophy
(DMD) and to tell you a little bit about where things
Received December 15, 2004; accepted for publication December
16, 2004; electronically published January 6, 2005.
Address for correspondence and reprints: Dr. Louis M. Kunkel, Di-
vision of Genetics and the Howard Hughes Medical Institute, Enders
570, Children’s Hospital Boston, 300 Longwood Avenue, Boston, MA
02115. E-mail: kunkel@enders.tch.harvard.edu
* Previously presented at the annual meeting of The American So-
ciety of Human Genetics, in Toronto, on October 29, 2004.
 2005 by The American Society of Human Genetics. All rights reserved.
0002-9297/2005/7602-0005$15.00
are currently going in muscular dystrophy research. But,
before getting into the muscular dystrophy gene–cloning
story, I’d like to tell you a little bit about the early work
that I did with the Y chromosome, because it fits with
the whole theme of what I’ve done with my life in re-
search. I will follow the Y-chromosome remarks with
the story behind the DMD gene cloning, its protein iden-
tification, and how this led to improved diagnosis of the
muscular dystrophies. I will also discuss some of the
biochemistry of the muscular dystrophies and the ap-
proaches we might take in therapy for the muscular dys-
trophies. I will close and go through a series of thanks
and acknowledgments to many of the past lab mem-
bers—because you’re honoring not just me, but my lab-
oratory over many years. You also honor all the scientists
and physicians who have collaborated with me over the
years. I would point out that probably as many as 300
people in the audience today will see their name some-
where through my talk or on one of my slides.
Now to the Y chromosome. The Y chromosome is a
unique entity in the sense that it’s isolated from the rest
of the genome. It should have sequences on it that are
specific to it. It is influential and plays the major role as
to whether you are male or female. And Dr. David Page
at MIT and a number of others have done very well in
characterizing the Y chromosome.
I started as a graduate student, with Drs. Kirby Smith
and Ned Boyer at Johns Hopkins University, with a hy-
pothesis that I could isolate from the Y-chromosome
DNA sequences that were present solely on the Y—that
weren’t present in female DNA. I used a subtractive-
hybridization strategy to enrich for those sequences on
the Y chromosome. And the Y-specific criteria would be
that they should hybridize solely to male DNA and not
to female DNA. You would expect that, if you had two
Y chromosomes, there would be twice as many se-
quences. Our paper describing our characterization of
these Y-chromosome sequences was kindly communi-
cated to PNAS by Dr. Victor McKusick (Kunkel et al.
1977). The Y-specific sequences failed to hybridize to
E. coli DNA and DNA isolated from a human female.
These same sequences hybridized to DNA isolated from
a human male. The reassociation kinetics to the male
DNA showed perfect hybridization kinetics and nearly
100% hybridization. Individuals with two Y chromo-
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somes or bearing an isochromosome of the long arm of
the Y showed a 2-fold increase in hybridization rate. It’s
almost like an RT-PCR reaction where you’re looking
at a 2-fold increase in amplification rate. The differential
subtractive hybridization described in his paper served
as the basis for some of the things that I’ll tell you later.
But this paper was most quoted, not for the Y chro-
mosome work, but for the method we used to prepare
DNA from whole human blood. And it was one of my
most-quoted papers over the history of my time in ge-
netics research.
Now let’s turn to Duchenne dystrophy and the iso-
lation of the gene altered in Duchenne muscular dystro-
phy. I came to Boston from San Francisco with the intent
to try to look at the X chromosome. The late Dr. Sam
Latt was starting to sort the human X chromosome, and
he wanted to make chromosome-specific recombinant
libraries from those chromosomes. And I proposed to
the Muscular Dystrophy Association in a fellowship ap-
plication that I would use those sorted chromosomes to
prepare DNA segments that I could use to try to map
the DMD gene. DMD, as you all know, is a very severe
X-linked recessive disorder and is one of the most com-
mon recessive disorders in the human population. It
presents in boys at ∼3–5 years of age, with patients
showing progressive muscle weakness. The progressive
muscle wasting leads to their being confined to wheel-
chairs, usually by the age of 9 or 10 years. One of the
hallmarks of this progressive muscle-wasting disease is
the histological appearance of the muscle. Normal mus-
cle, when stained with hemotoxlin and eosin, is highly
organized with regular-sized fibers. In contrast is the ob-
viously very disorganized muscle of a patient with Duch-
enne dystrophy, showing the connective tissue infiltra-
tion and hypertrophy of myofibers. You also see some
inflammation within the muscle and extensive deposits
of connective tissue.
The big question when I started this work in the early
1980s was how we could go about identifying the gene
responsible for this disorder without a known biochemi-
cal defect. We had a genetic disorder, but we had no
defective protein, as many had had before for diseases
such as the hemoglobinopathies and Lesch-Nyan syn-
drome. We did know that DMD resided on the human
X chromosome, because it was inherited as an X-linked
recessive trait.
Knowing that it was an X-linked disorder, the gene
responsible for Duchenne dystrophy must fall some-
where on the X chromosome. So, just by the process of
elimination, we’ve eliminated essentially 95% of the ge-
nome. But where on the X was the Duchenne gene? Well,
as I said, I joined Dr. Latt’s lab to do chromosome sort-
ing. The fluorescent-sort pattern of chromosomes from
a 46XY individual—that is, an individual with one X
chromosome—compared with that of an individual with
five X chromosomes, is quite different at the peak in which
the X falls. The peak containing the X chromosome is
much higher when there are five X chromosomes. We
were able to take segments of that peak, create an X
chromosome–specific phage recombinant DNA library,
and prepare DNA segments from that library (Kunkel
et al. 1982).
Unbeknownst to me, at the same time I was doing
this, Dr. Kay Davies at Saint Mary’s in London was
doing the same thing. And she actually published well
before me the cloning of a representative cDNA library
from which she derived segments of X-chromosome DNA
(Davies et al. 1981). We followed up with our publi-
cation the following year, with Dr. Latt as senior author
(Kunkel et al. 1982). We also used very similar methods
that I had used before with the Y chromosome, to show
that we could regionally localize the X-chromosome seg-
ments on the human X. Dr. Umadevi Tantravahi was
able to produce beautiful blots by using variant X-chro-
mosome rearrangements, with different chromosome-arm
copy numbers to localize the cloned segments.
We used the cloned X chromosome–DNA segments to
identify those that detected restriction-fragment–length
polymorphisms. Using a similar approach, Dr. Davies’
group was able to show that the Duchenne gene showed
linkage to markers from the short arm of the X chro-
mosome and that it could be flanked by two markers
(Davies et al. 1983). Thus, the DMD gene was in the
short arm of the human X. That was followed by Dr.
Peter Harper’s group showing that you could actually
map the less-common and milder form of the disease,
Becker muscular dystrophy, to the same region of the X
chromosome (Kingston et al. 1984). These clones that
detected restriction-fragment–lengthpolymorphismswere
used to do prenatal diagnosis of patients and of women
who were at risk of having kids with Duchenne dystro-
phy (Bakker et al. 1985).
A second, independent way that the Duchenne gene
was localized was done by a very astute set of geneticists,
mapping X-chromosome translocations in girls with Du-
chenne dystrophy. For one girl, Dr. Ron Worton and Dr.
Christine Verellen were able to show that the X chromo-
some was translocated to the region of chromosome 21
that contained the ribosomal genes (Verellen-Dumoulin
et al. 1984). The normal X chromosome was inactive
in almost all the cells of this girl. The abnormal, dis-
rupted chromosome was the active chromosome, and it
was thought that the disruption of that X chromosome
was the reason why this girl had muscular dystrophy.
The positioning of the DMD gene to that break point
within the ribosomal gene cluster led Dr. Ron Worton
to reason that he could use the junction fragment of the
translocation break point—a piece of the X chromosome
joined to a piece of a ribosomal gene—as a way to obtain
a portion of the DMD gene (Worton et al. 1984). He
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could use a ribosomal gene probe to try to pull out a
piece of the X chromosome. And presumably, if it was
broken in the Duchenne gene, he would pull out a piece
of the Duchenne gene at the same time. Numerous other
translocations that apparently disrupted the DMD gene
in females were described, and these were quite hetero-
geneous in their break-point position.
While Ron Worton was attempting to clone the trans-
location break point, my lab was working with a patient
who was first seen by Dr. Roberta Pagon, in Seattle, in
Dr. Hans Och’s group. The patient, B.B., had four X-
linked disorders: Duchenne muscular dystrophy, chronic
granulomotous disease, retinitis pigmentosa, and the rare
red-cell phenotype McLeod. Roberta reasoned that this
could be a contiguous-gene–deletion syndrome and asked
Dr. Christine Disteche, a cytogeneticist who had actually
just recently left a fellowship in Dr. Latt’s laboratory,
whether she could call this a “deletion.” Christine said
she felt she couldn’t but recommended one of the best
cytogeneticists in the country at the time, Dr. Uta Francke.
They sent cells from the patient to Dr. Francke, then at
Yale.
Dr. Francke felt very strongly that this was a deletion,
and a number of us—including Dr. Worton, Dr. van
Ommen and me—sent probes to her from the X-chro-
mosome short arm to test against DNA isolated from
various X-chromosome deletions, including those from
B.B., to see whether she could indeed document a de-
letion of the short arm of the X chromosome that might
be the cause of B.B.’s four genetic disorders (Francke et
al. 1985). In a parallel effort, I reasoned that we might
be able to use this DNA sample from this patient with
a deletion in the same way I did the Y-chromosome
work. That is, the patient should be missing DNA se-
quences that were present on a normal X chromosome,
and I should be able to set up an experiment that would
allow me to enrich for segments that were missing from
this child’s DNA.
DNA isolated from B.B. was sheared and mixed with
a small amount of DNA isolated from an individual who
had four X chromosomes. The “tracer DNA,” as it is
called, was cleaved with MboI, which left sticky ends
that were compatible for cloning with a BamH1 site.
The DNA from the patient was sheared, so it had blunt
ends and would not be compatible for cloning with a
BamHI site. We mixed them in a 200:1 ratio, and we
used a hybridization technique that Dr. Kirby Smith had
been working on while I was a graduate student at Hop-
kins, first described by Dr. David Kohne, called “phenol-
enhanced reassociation.” This was a way of getting the
unique sequence-tracer molecules in the mixture to self-
reassociate in the presence of this excess DNA when they
found no complementary strand in the excess DNA of
B.B.. Three types of hybridized molecules would form
those with both strands sheared—which was the majority
of the molecules, molecules with one strand sheared and
the other MboI ended; these are molecules that found a
complementary sequence in B.B.’s DNA. There would
also be a very minor population of MboI/MboI-ended
hybridized molecules that should be compatible with
closing within a vector cleaved with BamHI. These were
MboI-cleaved molecules that found no complement in
the deletion DNA but were able to self-hybridize to their
own complement.
While these experiments were developing, Dr. van Om-
men visited the lab in Boston and told us about a result
that he had found in collaboration with Dr. Uta Francke.
They had found a clone by the name of “754” that was
missing from B.B.’s DNA (Francke et al. 1985). We, at
the same time, were in the process of putting together
the publication that described the specific cloning of
DNA segments from the DNA isolated from the boy
(Kunkel et al. 1985). The seven so-called pERT clones
were completely absent from the DNA of the deletion
patient. So we now have segments of DNA from the X
chromosome that presumably are nearby or within the
four genes causing the complex phenotype of B.B.
How do you move from there? I had proposed to the
Muscular Dystrophy Association, in my first grant ap-
plication, that we might use these deletion clones to iden-
tify the DMD gene. B.B.’s DNA had this large deletion,
and we now had eight clones that were absent: seven
identified in our analysis and the 754 clone identified by
Drs. van Ommen and Francke. We knew from other X-
linked disorders that ∼5% of patients who had an X-
linked disorder had a small deletion as the cause of that
disorder. Some portion of the gene was missing. So the
idea was, why not take these clones absent from the
DNA isolated from the patient with the larger deletion
and scan 50 or so DMD patients for deletions in their
DNA at one of these loci. A deleted clone would likely
be the closest to the Duchenne gene. We gathered the
DMD patient DNA samples from our neuromuscular
clinic and those collected by Dr. Fischbeck, then at Penn,
and Dr. Roses, then at Duke. We were able to detect
deletions with the pERT 87 clone but with none of the
other clones (Monaco et al. 1985). This was the work
of a very talented graduate student, Dr. Tony Monaco.
Nearly coincident with our work, Dr. Peter Ray, with
Dr. Worton, was successful in cloning the ribosomal-
junction fragment from the translocation carrier female
and was also able to detect deletions with a clone from
a region that they termed the “XJ region” (Ray et al.
1985). So we had two independent clones from the X
chromosome that detected deletions.
These deletion-detecting clones were detecting the pri-
mary mutation in these boys with DMD, and the world
scientific community heard about this well before pub-
lication of the results. Duchenne muscular dystrophy is
such a common disorder, and physicians and patients were
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anxious for the ability to do diagnostics of DMD. We
made available the pERT 87 clone and surrounding sub-
clones of DNA to many investigators around the world,
some of whom are here in the audience. They contributed
results, each of them, on a set of patient DNA samples
in which they did deletion analysis. Overall,11,300 DMD
patients were analyzed for deletions at the pERT 87
locus, of which ∼8% were deleted for the pERT 87 clone
(Kunkel 1986). One of the conditions that we used for
allowing the clones to go to other people was that they
would send us the DNA samples of patients who were
detected as having deletions. We were then able to map
the deletion break points in the ever-growing chromo-
some walk that Tony Monaco was performing around
the pERT 87 (designated the “DX164”) locus. We found
that there were patients who had the telomeric pERT
87-27 subclone present and the remainder of the DX164
locus missing. There were also patients who had the
centromeric side of the DX164 locus present but the
remainder of the locus missing. Some of these centro-
meric deletions were also not deleted for XJ clones.
Many of the DX164 subclones detected restriction-frag-
ment–length polymorphisms, and these were being used
to track the DMD gene in families. Somewhat surpris-
ingly, some of these families exhibited recombination
between the marker and the disease phenotype. This
indicated that the mutation being followed was some-
place outside the DX164 locus.
We were finding recombinants that indicated that the
mutations were outside and in either direction from our
location on the X chromosome. We also knew that the
XJ locus was completely independent of the DX164 lo-
cus. So either we were in the wrong place or this was a
very large gene spaced over a very large distance. So
how does one find that large gene within the chromo-
some walk? Throughout the entire walk, we were look-
ing for direct evidence of transcription by testing the
unique sequence clones against cDNA libraries and
northern blots—to no avail.
We then decided to use a very systematic approach,
looking at sequence conservation among species, know-
ing that, for most cloned segments of genes, there is a
sufficient nucleotide homology between the species and
we should be able to pick up, by Southern-blot hybridi-
zation, the cross-species homology. Two segments of
DNA within this DX164 locus, PERT 87-4 and PERT
87-25, detected restriction fragments in DNA samples
isolated from bovine, cebus, hamster, mouse, and even
chicken. Both clones were sequenced by Tony Monaco
in both directions, in both mouse and human. A small
open reading was found in both species that was sur-
rounded by consensus splice sites. He used the clone as
a hybridization probe against a muscle-cDNA library
and was able to pick out a cDNA that hybridized eight
HindIII restriction fragments in human DNA. All the
hybridizing HindIII fragments were completely missing
from DNA isolated from B.B., and they were spaced over
the entire 210-kb phage walk of the DX164 locus (Mon-
aco et al. 1986).
On northern blots, the transcript that was detected by
this cDNA was 14 kb in size. Given the size of the tran-
script and the spacing of exons in the DX164 locus, the
prediction was that this was a large locus. A similar
result was found by Dr. Ron Worton’s group. Arthur
Burghes used chromosome walking and sequence con-
servation to identify a second set of cDNAs that was
nonoverlapping with those of the DX164 cDNAs, again
implying a very large locus (Burghes et al. 1987). During
this time, a number of people were also doing pulse-gel
electrophoresis and were documenting that this was an
enormous locus and that the Duchenne gene was there-
fore spaced over a very large area (Burmeister et al. 1986;
van Ommen et al. 1986). Tony Monaco later, after leav-
ing my laboratory, cloned the entire locus in overlapping
cosmids and was able to show that it was 2.5 million
bp from the first exon to the last exon of the gene. In
our era of the complete human sequence, the DMD gene
is annotated from 30 to 32.5 Mb on the X-chromosome
map. In most cases, if you looked at an interval of 2.5
Mb on the Web browser of genes within an interval,
you would expect to see 10–15 genes within the interval.
In the case of the Duchenne gene, only one gene is in
the interval. The DMD gene is the largest mammalian
locus encoding a single protein.
From the gene, I would like to now turn to the protein.
And this is a place where I actually could have used the
help of my dad, who had died just before all of this
research happened. He was an immunologist, and I had
to now become an immunologist. Eric Hoffman joined
the lab as a postdoctoral fellow and started to work
with making fusion peptides, expressing pieces of the
DMD gene and putting them into both rabbits and
sheep, and creating antibodies against these fusion pep-
tides. He used two fusion peptides, one of 30 kDa and
a second of 60 kDa. These were injected into rabbits
and were used to look for the DMD gene–encoded pro-
tein on western blots. While he was doing this, the group
at Columbia had heard that this was a huge gene with
a very large transcript and that there was a known gene
expressed in muscle, nebulin, which encoded a 600-kDa
protein, and proposed nebulin as the candidate for the
Duchenne gene (Wood et al. 1987). Just after that report,
Eric Hoffman was able to show that it wasn’t a 600-
kDa protein; it was actually a 400-kDa protein, which
we named “dystrophin” (Hoffman et al. 1987a). The
name was based on the fact that we had used patient
samples from kids with muscular dystrophy as a source
of the DNA to identify this gene and the encoded pro-
tein. Most muscle-expressed proteins ended with “in,”
so “dystroph-in.”
Kunkel: 2004 William Allen Award 209
Once you have antibodies, you can ask, where is the
protein? Eric Hoffman was forced to use western blots
and membrane purifications, because the antibodies
crossreacted with a-actinin. In collaboration with Dr.
Kevin Campbell, we showed that dystrophin copurified
with membranes and that those membranes were sup-
posedly most enriched with the triad structures of muscle
(Hoffman et al. 1987b). Well, it turns out that dystro-
phin was not localized to the triads, but it was localized
to the plasma membrane, which contaminated our mem-
brane preps. This sarcolemmal localization was very ele-
gantly shown by Drs. Elizabeth Zubrzycka-Gaarn and
Kichi Arahata independently, sadly neither of whom is
with us any longer (Arahata et al. 1988; Zubrzycka-
Gaarn et al. 1988). They were able to localize dystrophin
to the plasma membrane of a muscle cell. We, working
with Dr. Edwardo Bonilla, were able to show the same
thing a few months later (Bonilla et al. 1988).
Dr. Michael Koenig joined the laboratory and was
responsible for cloning the entire 14-kb transcript as
overlapping cDNA clones (Koenig et al. 1987). He se-
quenced it manually, not with a machine. And it took
him 6 mo to sequence that entire 14-kb transcript. It
was predicted to be a rodlike structure and, because it
underlay the plasma membrane, he felt it played a role
in membrane stability under contraction and relaxation
of muscle (Koenig et al. 1988).
The work outlined here led to improved diagnostics.
The dystrophin gene, being so big, is an enormous target
for deletion mutations. Dr. Jeff Chamberlain, working
with Dr. Tom Caskey at Baylor, was able to develop a
deletion-screening procedure that used multiplex PCR
(Chamberlain et al. 1988). And Dr. Alan Beggs in my
group was able to elaborate on that and show that we
could pick up, by multiplex PCR, ∼98% of all deletion
mutations at the dystrophin locus (Beggs et al. 1990).
This led to a very rapid and inexpensive molecular test
for the most commonly deleted exons.
This is the method that’s still in use today for diagnosis
of ∼65% of patients with Duchenne dystrophy. This
leaves many patients without a molecular diagnosis,
which is a serious drawback and somewhat unfair to
the patients with muscular dystrophy. It’s just recently
that Dr. Kevin Flanigan has actually worked out a very
high-throughput robotic sequencing strategy to look at
all mutations in the dystrophin gene (Flanigan et al.
2003). We’ll see later that some therapies being devel-
oped are mutation specific. We are working with Applied
Biosystems to work on a modification of his protocol to
look at point mutations at the dystrophin locus in a very
high-throughput, rapid, robust way (Bennett et al.
2004). We are also targeting all the genes involved in
all the different types of muscular dystrophy. I believe
improved DNA diagnostics is one of the great unmet
needs in muscular dystrophy research.
Protein-based diagnostics were developed first by Dr.
Eric Hoffman in collaboration with a group of referring
physicians. He was able to show that patients with
Duchenne dystrophy made virtually no or very small
amounts of very-abnormal-sized protein, whereas pa-
tients with milder Becker dystrophy made an internally
truncated protein of near-normal abundance (Hoffman
et al. 1988). These protein-based tests, both by western
blotting and immunohistochemistry, have become the
standard of care for diagnosis of X-linked dystrophy.
Carrier females can also be detected and are mosaics for
dystrophin deficiency, with some fibers missing dystro-
phin where the normal X has been inactivated and some
fibers where dystrophin is present. This is quite diag-
nostic of carrier females. Tony Monaco, in a paper that
was published in the January issue of Genomics, with a
received date in February, explained our hypothesis about
the difference between a deletion yielding a patient with
Duchenne dystrophy and a deletion in a patient with
Becker dystrophy (Monaco et al. 1988). The deletions
in patients with Becker dystrophy retained the reading
frame of the protein, whereas the deletions of patients
with Duchenne dystrophy disrupted it.
Now dystrophin doesn’t work alone, and the identi-
fication of dystrophin led to a complete set of unique
membrane proteins that had previously been unrecog-
nized. Much of this work was accomplished by pulling
dystrophin out of muscle with an antibody and by asking
what else came along with it. This work was first really
pioneered by our early collaborator, Dr. Kevin Campbell;
he showed that there was an integral lack of a protein
named “dystroglycan” that was associated with dystro-
phin (Campbell et al. 1989). Campbell et al. showed
that there are actually a number of other proteins that
interacted with dystrophin, and they proposed a model
of this interaction, termed the “dystrophin-associatedpro-
tein complex,” or DAPC (Ervasti and Campbell 1991).
At the same time, Dr. Ozawa’s group in Japan was
doing similar fractionations of dystrophin and its asso-
ciated proteins and was able to show that the dystrophin-
associated proteins actually separated into two classes:
those that were of the dystroglycan complex and those
that were of the sarcoglycan complex (Yoshida and
Ozawa 1990; Yamamoto et al. 1993). The sarcoglycans
were quite interesting, because the first one cloned, en-
coding a 50-kDa protein, was one that was localized by
Dr. Campbell’s group and was found to be completely
missing from the muscle of a patient with limb-girdle
dystrophy, which was endemic within the Tunisian popu-
lation (Matsumura et al. 1992). That dystrophy was
mapped, by Dr. Jeff Vance’s group in collaboration with
Dr. Ben Hamida, to chromosome 13 (Othmane et al.
1992). The 50-kDa protein was actually encoded by a
locus on chromosome 7.
So this made things a bit confusing, but it was clear
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that there was a form of autosomal recessive dystrophy
on chromosome 7 (Roberds et al. 1994). The second of
the sarcoglycans was cloned independently by both Dr.
Campbell’s group in collaboration with Dr. Charles
Jackson and by us in collaboration with Dr. Ozawa. This
protein was named “b-sarcoglycan” after these two pa-
pers went into Cell at the same time and were rejected
as redundant with each other. The reviewers asked us
to give the protein the same name. Dr. Jackson had iden-
tified Amish families that were segregating a recessive
dystrophy that mapped to chromosome 4, a location to
which the b-sarcoglycan clone mapped (Lim et al. 1995).
Dr. Bonnemann used a panel of patients with dystrophy,
provided to us by Dr. Eric Hoffman, to look for a patient
who might have a mutation in the b-sarcoglycan gene
(Bonnemann et al. 1995). This work was followed by
the cloning of the chromosome 13 gene, which encoded
the g-sarcoglycan gene, work Dr. Elizabeth McNally in
my group did in collaboration with Dr. Ozawa (Noguchi
et al. 1995). Subsequently, Dr. Vincenzo Nigro was able
to use a chimeric cDNA clone and to show that the g-
sarcoglycan gene had a homolog—which he called “d-
sarcoglycan”—on chromosome 5, a location to which
Mayana Zatz had just mapped a familial dystrophy lo-
cus. I actually reviewed both papers and believe that I
indirectly showed the two groups that one has the gene
and one has the locus. The groups got together, and that
led to their identification of mutation in the d-sarcogly-
can gene in this recessive form of muscular dystrophy
(Nigro et al. 1996).
Over the years, the dystrophin-associated–proteincom-
plex, DAPC, has evolved as more and more proteins are
shown to associate in it, and at least half the members
of this complex are themselves involved in forms of mus-
cular dystrophy; most were identified by biochemistry.
That is, they were identified as part of this complex and
then were tested in patients with different forms of mus-
cular dystrophy. And this has been the work of many,
many people. We believe this is the complex that sta-
bilizes the plasma membrane of muscle and that, when
it contracts and relaxes, the membrane is inherently un-
stable when it is compromised by mutation in these pro-
teins. The membrane tears and allows calcium to influx
into the cell, causing proteolytic degradation via calcium-
activated proteins. There is still a lot of work to be done
on the pathogenesis, and we still need to explain how
all these different forms of muscular dystrophy—some
of which aren’t really immediately biochemically related
to one another—actually give rise to similar muscular
wasting seen in patients.
I would like to end the overview session with thera-
peutic approaches to muscular dystrophy. We’ve learned
a lot, but it’s been 18 years since the Duchenne gene
was cloned, yet there’s still no therapy other than the
anabolic steroid, prednisone, that’s useful for these kids.
Now that’s really a travesty—that we’ve gone that long
and we still don’t have therapies. But I should say, there
is an enormous number of possibilities coming. I didn’t
talk at all about utrophin because I just really didn’t
have time, but much of it is the work of Dr. Kay Davies
and a past student of mine, Dr. Teji Khurana, and it’s
really fantastic. Dr. Davies has shown that utrophin will
actually correct for absent dystrophin, and upregulation
of utrophin could correct for the absence of dystrophin
(Tinsley et al. 1998).
I will touch on exon skipping, antibiotic use, and some
gene- and cell-based therapies, ending with the cell-based
therapies, something that my group has been involved
with from the very beginning. We need an animal model
of muscle disease, and there is a model. There are ac-
tually five alleles of that model now, the mdx mouse first
published as a point mutation in exon 23 (Sicinski et al.
1989). The mouse makes no dystrophin yet lives a nor-
mal life span with minimal muscle weakness. The effort
is on to correct for absent dystrophy. Dr. Jeff Cham-
berlain’s group very elegantly showed that if you trans-
genically overexpress dystrophin in this animal model,
it could completely restore dystrophin expression and it
could actually restore functional characteristics (Cox et
al. 1993). In addition, overexpression wasn’t toxic to
the muscle cell. So, if you put the dystrophin back, you’d
actually correct the problem. So that’s what all of us
have been trying to do, correct the problem by restoring
dystrophin expression by some means.
Dr. Lee Sweeney’s group, working with antibiotics,
was able to show that if you treated mdx mice with
G418, an antibiotic, you could actually get some res-
toration of dystrophin expression to the membrane and
actually get some improvement in the serum creatine-
kinase levels (Barton-Davis et al. 1999). This has actually
led to an effort at a company to find additional molecules
that will do this much more efficiently. And Lee has
talked about a compound by the name of “PTC124,”
which actually looks as if it works better than the anti-
biotics. That is now going to toxicity testing. This is very
promising but will work on only point mutations that
result in a premature stop codon.
A number of groups have looked at exon skipping. It’s
something we talked about, Tony Monaco and I, many,
many years ago—about trying to fool the splicing ma-
chinery into removing exons that contained a mutation.
Dr. Steve Wilton, along with Dr. Terry Partridge, has
been able to show that you can actually restore dystro-
phin expression when the mouse muscle is exposed to
an oligonucleotide against one of the spliced sites (Mann
et al. 2001). In Europe, they are also starting human
experiments to actually look and see whether they can
do this read-through in human patients.
Myostatin is a negative regulator of muscle develop-
ment. It has been shown by Dr. Teji Khurana, a past
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student of mine, in collaboration with Wyeth, that if
you downregulate or if you reduce the levels of myo-
statin, you actually build up muscle (Bogdanovich et al.
2002). Myostatin-null mice and myostatin-null cattle
have about twice the muscle mass of a normal mouse
or a normal cow. Wyeth is actually in human trials to
try to knock myostatin levels down in three forms of
muscular dystrophy.
Lastly, Dr. Jeff Chamberlain has just recently reported
a very nice systemic delivery of microdystrophin to the
muscle of the mdx mouse (Gregorevic et al. 2004). The
work was presented in a platform session on Saturday,
during the ASHG annual meeting, by Paul Gregorick;
he’s been able to systemically deliver a microdystrophin
in AAV6 that actually restores function to the muscle.
This vector appears to nearly completely restore dystro-
phin expression in these animals. This is an amazing
amount of expression, and they’re actually gearing up to
do human trials with these vectors and microdystrophin.
I’ll end my talk by discussing cell transplantation.
Muscles are a regenerative tissue, and I’ve felt all along
that you should be able to take the mononuclear cells
called “myoblasts” from a normal individual and intro-
duce them into the muscle of a patient with muscular
dystrophy. These should fuse to pre-existing fibers and
produce absent gene products, such as dystrophin. My
group has been working on this for many years, along
with Dr. Terry Partridge and a number of others. With
Dr. Partridge, we were able to convert mdx fibers from
dystrophin-negative to -positive by introduction of fetal
mouse–muscle progenitor cells (Partridge et al. 1989).
This work led to a series of human experiments with
so-called myoblast transfer; all of which really didn’t work
(Gussoni et al. 1992; Huard et al. 1992; Karpati et al.
1993; Mendell et al. 1995). This led us to go back to the
drawing board and ask whether there were additional
ways one could identify cells that had a much higher
fusion index. We took advantage of our close proximity
to Dr. Richard Mulligan, who was using Hoechst dye
to sort bone-marrow stem cells. This was actually a dye
we had used many years before in our chromosome sort-
ing. The stem cells of the marrow, when stained, were
able to efflux the Hoechst dye, leaving a less brightly
stained group of cells, termed “side population” (SP).
These same cells isolated from muscle were able to re-
store the hematopoetic compartment and could system-
ically traffic from the circulation into muscle and that
could contribute to muscle regeneration (Gussoni et al.
1999). We are working to improve this trafficking and,
in collaboration with Dr. Jeff Chamberlain, we have
transduced the cells with a lentivirus expressing a micro-
dystrophin. Only SP cells are recruited into damaged
muscle, indicating that they were enriched and repre-
sented some kind of a progenitor cell. By this intravenous
delivery system, we were able to produce human mi-
crodystrophin in the mouse muscle; a bit !1% of the
fibers expressed the human protein (Bachrach et al.
2004)—far below what would be considered therapeu-
tically useful.
A second delivery method, developed by Dr. Giulio
Cossu, is to introduce the cells intra-arterially—unlike
intravenous delivery where the cells would be filtered
through various different organs of the animal. The cells
go directly to the muscle with arterial delivery. And the
arterial delivery gives you a much more substantial in-
graftment of these cells. Indeed, in Dr. Cossu’s hands,
using a model of a-sarcoglycan muscular dystrophy, he
could actually restore function with arterial delivery of
a stem cell, which bodes very, very well for therapy (Sam-
paolesi et al. 2003). Actually, I’ve heard that, in Italy,
they’re actually contemplating human trials of interar-
terially delivered stem cells. Indeed, we presented a pa-
tient a few years ago, in collaboration with Dr. Ken
Weinberg, who had been transplanted with bone mar-
row and who still has residing within his muscle—many
years later—donor cells from that transplant (Gussoni
et al. 2002). Those donor cells, though, were so ineffi-
cient at producing dystrophin that they are not at all
corrective. This first serendipitous use of bone-marrow
transplant in DMD is interesting and does indicate that
cells can be recruited from the circulation, albeit at very
low efficiency.
Where are we now? What do we need? I think we
need very-much-improved DNA diagnostics. We are do-
ing a disservice to patients who don’t carry a molecular
diagnosis. I think we’re getting close to newborn screen-
ing, something I feel is important, because, if you re-
member that muscle cross section of DMD muscle that
I showed you, the damage is so great, even in the muscle
of a 5 year old, that whatever treatment we use will need
to be done sooner, before the muscle damage occurs. We
need to understand the pathogenesis of the disease. As
I talked about earlier, small-molecule and gene stem-cell
therapy are all moving forward.
In ending, I’d like to acknowledge the Muscular Dys-
trophy Association for their support over the many years,
including that first grant, which came from them to get
me started. The NIH, NICHD, NINDS, NIAMS, NIA,
and the Institute of Aging are actually unrelated to this.
This is my longevity work. I have been hugely fortunate
to be an Investigator in the Howard Hughes Medical
Institute for many years. I’ve also been fortunate to have
the support of many, many families of patients with mus-
cular dystrophy.
I will close with a few slides of my lab over the years,
giving tribute to the late Dr. Sam Latt, who mentored
me through much of this work. I think he would have
been up here well before me receiving this award, be-
cause his thoughtfulness and creativity were enormous.
I thank all past members of the lab whom I may not have
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acknowledged during my talk. Lastly, I’d like to thank
my family, who has been so supportive over these years.
And I also thank you all for listening.
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